Index S&P 500
P/E -
EPS (ttm) -3.10
Insider Own 0.08%
Shs Outstand 2.03B
Perf Week -9.52%
Market Cap 89.62B
Forward P/E 6.37
EPS next Y 6.94
Insider Trans 0.84%
Shs Float 2.03B
Perf Month -16.17%
Income -6148.00M
PEG -
EPS next Q 1.68
Inst Own 78.38%
Short Float 1.70%
Perf Quarter -9.54%
Sales 45.53B
P/S 1.97
EPS this Y -92.88%
Inst Trans -0.74%
Short Ratio 2.11
Perf Half Y -13.74%
Book/sh 8.14
P/B 5.43
EPS next Y 1198.35%
ROA -6.36%
Short Interest 34.36M
Perf Year -35.37%
Cash/sh 4.77
P/C 9.27
EPS next 5Y -4.17%
ROE -25.45%
52W Range 43.93 - 69.10
Perf YTD -13.84%
Dividend Est. 2.41 (5.45% )
P/FCF 7.16
EPS past 5Y 5.14%
ROI -9.10%
52W High -36.02%
Beta 0.44
Dividend TTM 2.34 (5.29% )
Quick Ratio 0.99
Sales past 5Y 16.92%
Gross Margin 55.85%
52W Low 0.64%
ATR (14) 1.05
Dividend Ex-Date Apr 04, 2024
Current Ratio 1.11
EPS Y/Y TTM -189.43%
Oper. Margin 16.55%
RSI (14) 24.54
Volatility 2.97% 1.90%
Employees 34100
Debt/Eq 3.48
Sales Y/Y TTM -0.68%
Profit Margin -13.50%
Recom 2.64
Target Price 53.11
Option/Short Yes / Yes
LT Debt/Eq 3.10
EPS Q/Q -650.00%
Payout 59.82%
Rel Volume 0.81
Prev Close 43.94
Sales Surprise 3.34%
EPS Surprise 0.28%
Sales Q/Q 4.66%
Earnings Apr 25 BMO
Avg Volume 16.26M
Price 44.21
SMA20 -9.06%
SMA50 -12.83%
SMA200 -18.02%
Trades
Volume 13,244,338
Change 0.61%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-11-24 Downgrade
Societe Generale
Buy → Hold
Feb-06-24 Downgrade
Redburn Atlantic
Buy → Neutral
$77 → $54
Jan-03-24 Downgrade
BofA Securities
Buy → Neutral
$68 → $60
Nov-15-23 Downgrade
Cantor Fitzgerald
Overweight → Neutral
$68 → $55
Nov-09-23 Initiated
Deutsche Bank
Hold
$55
Nov-02-23 Downgrade
Daiwa Securities
Outperform → Neutral
$68 → $54
Oct-27-23 Upgrade
HSBC Securities
Reduce → Hold
$55 → $53
Oct-27-23 Downgrade
William Blair
Outperform → Mkt Perform
Oct-27-23 Downgrade
BMO Capital Markets
Outperform → Market Perform
$60
Oct-20-23 Resumed
UBS
Neutral
$70 → $60
Jul-14-23 Initiated
HSBC Securities
Reduce
$56
Jul-10-23 Initiated
SVB Securities
Market Perform
$66
Jun-28-23 Initiated
Daiwa Securities
Outperform
$70
Mar-06-23 Initiated
Jefferies
Hold
$62
Jan-17-23 Initiated
Cantor Fitzgerald
Overweight
$95
Nov-18-22 Initiated
Credit Suisse
Neutral
$78
Oct-10-22 Downgrade
Guggenheim
Buy → Neutral
Sep-14-22 Downgrade
Berenberg
Buy → Hold
$82 → $76
Jun-03-22 Downgrade
Raymond James
Outperform → Mkt Perform
Apr-06-22 Resumed
Morgan Stanley
Underweight
$64
Show Previous Ratings
May-01-24 08:00AM
Apr-30-24 01:52PM
08:37AM
05:00AM
Apr-29-24 06:00AM
06:59AM
Loading…
Apr-26-24 06:59AM
Apr-25-24 04:41PM
(Yahoo Finance Video) -8.51%
03:35PM
02:02PM
01:32PM
11:55AM
11:50AM
11:48AM
11:42AM
(The Wall Street Journal)
09:49AM
(The Wall Street Journal)
06:59AM
Loading…
06:59AM
Apr-22-24 01:56PM
06:59AM
Apr-11-24 09:10AM
Apr-08-24 11:30AM
07:00AM
Apr-06-24 08:47PM
01:15PM
01:15PM
Apr-05-24 09:05AM
Apr-02-24 08:08PM
02:30PM
Apr-01-24 07:30AM
Mar-31-24 08:35AM
Mar-29-24 12:09PM
09:45AM
Loading…
09:45AM
Mar-28-24 04:05PM
04:01PM
07:30AM
Mar-26-24 07:19AM
06:59AM
Mar-25-24 08:21AM
08:00AM
Mar-21-24 03:00PM
(The Wall Street Journal)
Mar-20-24 04:45PM
08:58AM
06:59AM
Mar-19-24 06:59AM
Mar-18-24 07:32PM
(The Wall Street Journal)
09:52AM
08:44AM
08:00AM
Mar-15-24 06:27PM
12:17PM
Mar-14-24 09:35PM
10:56AM
Mar-13-24 09:03AM
Mar-12-24 08:30AM
Mar-11-24 04:16PM
07:56AM
Mar-07-24 02:23PM
09:10AM
Mar-06-24 04:17PM
Mar-05-24 10:38AM
09:06AM
02:56AM
Mar-04-24 09:06AM
Mar-01-24 04:16PM
Feb-29-24 06:59AM
Feb-28-24 07:34AM
Feb-26-24 04:16PM
08:35AM
Feb-25-24 05:46PM
Feb-24-24 02:31PM
Feb-23-24 06:59AM
06:59AM
Feb-22-24 07:00AM
Feb-20-24 06:59AM
06:30AM
(The Wall Street Journal)
Feb-14-24 07:57PM
04:16PM
08:30AM
06:59AM
Feb-12-24 06:59AM
Feb-07-24 08:55AM
06:59AM
Feb-05-24 09:20AM
06:59AM
Feb-03-24 08:49AM
Feb-02-24 11:37AM
10:58AM
07:26AM
06:59AM
Feb-01-24 05:23PM
09:29AM
(The Wall Street Journal)
05:30AM
(The Wall Street Journal)
Jan-30-24 09:15AM
06:59AM
Jan-27-24 10:00AM
Jan-26-24 07:13AM
Jan-23-24 08:30AM
Jan-22-24 05:05PM
05:00PM
Jan-20-24 10:00AM
Jan-18-24 02:41PM
(The Wall Street Journal)
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Shanahan Karin EVP, Glob. Prod. Dev. & Supply Apr 01 '24 Option Exercise 0.00 3,306 0 6,532 Apr 02 06:45 PM Lenkowsky Adam EVP, Chief Commercial Officer Mar 10 '24 Option Exercise 0.00 15,016 0 13,859 Mar 12 09:54 PM LEUNG SANDRA EVP, General Counsel Mar 10 '24 Option Exercise 0.00 46,784 0 371,312 Mar 12 09:43 PM Plenge Robert M EVP, Chief Research Officer Mar 10 '24 Option Exercise 0.00 9,143 0 15,182 Mar 12 09:21 PM Poole Ahn Amanda EVP, Chief Human Resources Mar 10 '24 Option Exercise 0.00 5,458 0 4,841 Mar 12 09:11 PM Hirawat Samit EVP,Chief Med.Offr.,Drug Dev. Mar 10 '24 Option Exercise 0.00 38,388 0 80,256 Mar 12 08:40 PM Holzer Phil M SVP and Controller Mar 10 '24 Option Exercise 0.00 5,520 0 14,916 Mar 12 08:31 PM Hoch Lynelle President, Cell Therapy Org. Mar 10 '24 Option Exercise 0.00 4,351 0 3,781 Mar 12 08:01 PM Gallman Cari EVP, Corporate Affairs Mar 10 '24 Option Exercise 0.00 2,761 0 2,655 Mar 12 08:00 PM BOERNER CHRISTOPHER S. Chief Executive Officer Mar 10 '24 Option Exercise 0.00 54,638 0 129,769 Mar 12 07:58 PM Elkins David V EVP, Chief Financial Officer Mar 10 '24 Option Exercise 0.00 64,326 0 225,111 Mar 12 05:43 PM Caforio Giovanni Executive Chair of the Board Mar 10 '24 Option Exercise 0.00 190,130 0 529,662 Mar 12 05:42 PM Meyers Gregory Scott EVP, Chief Digital & Tech Off. Feb 01 '24 Option Exercise 0.00 2,543 0 6,040 Feb 05 07:10 PM BOERNER CHRISTOPHER S. Chief Executive Officer Dec 05 '23 Buy 49.78 2,000 99,560 82,672 Dec 07 06:06 PM Plenge Robert M EVP, Chief Research Officer Dec 02 '23 Option Exercise 0.00 616 0 7,200 Dec 05 06:23 PM Elkins David V EVP, Chief Financial Officer Dec 02 '23 Option Exercise 0.00 8,792 0 172,342 Dec 05 06:22 PM BOERNER CHRISTOPHER S. Chief Executive Officer Dec 02 '23 Option Exercise 0.00 2,638 0 82,022 Dec 05 06:21 PM BOERNER CHRISTOPHER S. Chief Executive Officer Nov 28 '23 Buy 48.86 3,071 150,049 79,384 Nov 30 06:32 PM Samuels Theodore R. II Director Nov 20 '23 Buy 49.81 8,500 423,385 35,500 Nov 21 07:01 PM Powell Ann EVP, Chief Human Resources Aug 24 '23 Sale 61.25 17,986 1,101,642 27,868 Aug 28 05:28 PM Plenge Robert M EVP, Chief Research Officer Aug 03 '23 Sale 61.14 732 44,754 6,584 Aug 07 05:24 PM Weese Michelle EVP, Corporate Affairs Jul 01 '23 Option Exercise 0.00 1,885 0 4,135 Jul 05 05:26 PM Hirawat Samit EVP,Chief Med.Offr.,Drug Dev. Jul 01 '23 Option Exercise 0.00 9,357 0 52,032 Jul 05 05:23 PM Lenkowsky Adam EVP, Chief Commercial Officer Jun 03 '23 Option Exercise 0.00 1,077 0 1,077 Jun 06 07:39 PM VESSEY RUPERT EVP & President, Research May 03 '23 Sale 67.06 50,385 3,378,818 47,751 May 04 05:51 PM
Index S&P 500
P/E 14.35
EPS (ttm) 5.03
Insider Own 1.03%
Shs Outstand 534.48M
Perf Week -5.17%
Market Cap 38.56B
Forward P/E 9.52
EPS next Y 7.59
Insider Trans -0.40%
Shs Float 528.16M
Perf Month -0.28%
Income 2.73B
PEG 1.23
EPS next Q 1.98
Inst Own 95.15%
Short Float 1.44%
Perf Quarter -4.06%
Sales 155.52B
P/S 0.25
EPS this Y 2.33%
Inst Trans -1.30%
Short Ratio 2.39
Perf Half Y 6.31%
Book/sh 50.44
P/B 1.43
EPS next Y 11.05%
ROA 3.30%
Short Interest 7.59M
Perf Year 5.31%
Cash/sh -
P/C -
EPS next 5Y 11.71%
ROE 10.52%
52W Range 60.83 - 81.42
Perf YTD -2.64%
Dividend Est. -
P/FCF 14.81
EPS past 5Y 17.00%
ROI 6.10%
52W High -11.26%
Beta 0.41
Dividend TTM -
Quick Ratio -
Sales past 5Y 21.54%
Gross Margin -
52W Low 18.77%
ATR (14) 1.95
Dividend Ex-Date -
Current Ratio 1.17
EPS Y/Y TTM 89.85%
Oper. Margin 2.27%
RSI (14) 39.75
Volatility 3.17% 2.41%
Employees 76000
Debt/Eq 0.67
Sales Y/Y TTM 6.34%
Profit Margin 1.76%
Recom 2.05
Target Price 89.50
Option/Short Yes / Yes
LT Debt/Eq 0.66
EPS Q/Q 5.94%
Payout 0.00%
Rel Volume 1.37
Prev Close 73.06
Sales Surprise 10.91%
EPS Surprise 9.50%
Sales Q/Q 3.90%
Earnings Apr 26 BMO
Avg Volume 3.17M
Price 72.25
SMA20 -1.58%
SMA50 -5.08%
SMA200 -0.13%
Trades
Volume 4,361,043
Change -1.11%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-21-24 Downgrade
Stephens
Overweight → Equal-Weight
$92 → $85
Mar-06-24 Initiated
Barclays
Overweight
$101
Jan-02-24 Upgrade
Wells Fargo
Equal Weight → Overweight
$82 → $90
Sep-05-23 Upgrade
BofA Securities
Underperform → Neutral
$79 → $72
Aug-30-23 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$94 → $73
Jul-12-23 Downgrade
Wolfe Research
Outperform → Peer Perform
Jun-20-23 Initiated
UBS
Neutral
$72
Apr-21-23 Initiated
Cantor Fitzgerald
Overweight
$80
Mar-08-23 Downgrade
Deutsche Bank
Buy → Hold
$94 → $79
Feb-23-23 Downgrade
JP Morgan
Overweight → Neutral
$94 → $90
Dec-13-22 Downgrade
BofA Securities
Neutral → Underperform
$100 → $85
Sep-30-22 Initiated
Argus
Buy
$90
Aug-26-22 Downgrade
Wells Fargo
Overweight → Equal Weight
$103 → $99
Jul-28-22 Resumed
Barclays
Overweight
$107
Jul-14-22 Upgrade
Jefferies
Hold → Buy
$82 → $115
Jun-21-22 Upgrade
Credit Suisse
Neutral → Outperform
$86 → $88
Jun-17-22 Initiated
Loop Capital
Buy
$100
May-27-22 Resumed
Bernstein
Outperform
$111 → $108
May-26-22 Downgrade
BofA Securities
Buy → Neutral
$95 → $90
Jan-07-22 Resumed
Barclays
Overweight
$95
Show Previous Ratings
May-01-24 12:28PM
09:50AM
Apr-30-24 11:23AM
07:19AM
07:19AM
09:45AM
Loading…
Apr-29-24 09:45AM
Apr-27-24 03:04AM
01:05AM
Apr-26-24 11:26PM
(Thomson Reuters StreetEvents)
01:45PM
12:11PM
11:31AM
10:53AM
09:30AM
08:54AM
07:31AM
Loading…
07:31AM
07:11AM
06:26AM
06:16AM
06:14AM
(Associated Press Finance)
06:06AM
06:00AM
Apr-24-24 12:34PM
Apr-23-24 01:36PM
09:15AM
Apr-19-24 10:00AM
Apr-16-24 12:15PM
(The Wall Street Journal)
08:30AM
(Investor's Business Daily)
Apr-15-24 05:13PM
04:17PM
09:34AM
Loading…
09:34AM
(Investor's Business Daily)
04:50AM
Apr-11-24 10:50AM
05:34AM
04:00AM
Apr-09-24 04:30PM
12:47PM
Apr-08-24 05:51PM
09:40AM
07:41AM
06:36AM
Apr-02-24 04:50PM
10:00AM
(The Wall Street Journal)
07:31AM
Apr-01-24 10:32PM
11:17AM
08:40AM
Mar-30-24 06:50AM
Mar-29-24 04:28PM
Mar-27-24 08:58AM
08:00AM
Mar-26-24 06:51PM
Mar-25-24 02:30PM
Mar-18-24 10:00AM
09:58AM
09:40AM
Mar-17-24 12:55PM
Mar-14-24 08:45AM
Mar-13-24 10:13AM
Mar-12-24 06:00AM
Mar-10-24 08:29AM
Mar-07-24 12:15PM
11:31AM
06:01AM
Mar-05-24 06:03AM
Mar-04-24 09:50AM
Mar-01-24 12:23PM
Feb-29-24 04:30PM
09:00AM
Feb-28-24 08:00AM
Feb-21-24 09:40AM
09:40AM
Feb-20-24 11:00AM
10:15AM
04:03AM
Feb-16-24 01:58PM
06:03AM
Feb-15-24 11:00AM
Feb-14-24 12:45PM
07:36AM
Feb-13-24 10:00AM
Feb-11-24 08:00AM
(The Wall Street Journal)
Feb-09-24 02:21AM
Feb-08-24 09:45AM
Feb-07-24 10:50AM
Feb-06-24 11:58PM
(Thomson Reuters StreetEvents)
11:49PM
01:00PM
12:30PM
12:19PM
09:30AM
07:03AM
06:35AM
06:26AM
06:23AM
(Associated Press Finance)
06:21AM
06:17AM
06:16AM
06:08AM
06:00AM
Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options' vision and dental services, clinical healthcare, behavioral health, international operations, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Robinson Lori Jean Director Feb 13 '24 Option Exercise 54.65 10,000 546,500 21,455 Feb 15 06:31 PM Robinson Lori Jean Director Feb 13 '24 Sale 77.41 10,000 774,100 11,455 Feb 15 06:31 PM FASOLA KENNETH J President Feb 07 '24 Sale 75.07 12,000 900,817 235,365 Feb 08 07:38 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite